Skip to Main Content
Skip Nav Destination

Industry News + Events

We thank our industry partners and advertisers for supporting JIPO, and we encourage our readers to explore the latest headlines from these organizations below. 


ESID 2022: 20th Biennial Meeting of The European Society for Immunodeficiencies

12-15 October 2022, Gothenburg, Sweden

The deadline for late-breaking abstract submission is 23 August 2022.

Don’t miss the chance to showcase your valuable research at ESID 2022!

ESID 2022 offers an international stage for everyone interested in the immunodeficiency field and we would love to have you with us.          

The Meeting will provide a high-quality scientific program with a mixture of plenary sessions, parallel sessions, industry symposia and much more. We strive to offer you a diverse program so that you can hear the latest science from all disciplines of primary immunodeficiency.

Following the live Meeting, the content will also be accessible online.

See you in October!


12th International Gastrointestinal Cancers Conference

Dear Colleagues,

This year we are organizing the 12th International Gastrointestinal Cancers Conference (IGICC2022) between 1–4 December 2022 in Istanbul Turkey.

Considering the success of the first eleven conferences 12th IGICC will be again an indispensable opportunity for education and update of the treatment of gastrointestinal cancers, providing a clear overview for treatment, with the focus on individualized, multidisciplinary approach with the participation of broad range of experts. Besides educational sessions high quality abstracts are welcomed for presentation in oral and poster sessions.

Our conference will include all gastrointestinal, hepatobiliary, pancreatic malignancies as well as NETs, GISTs and gastrointestinal lymphomas and issues related to the care of patients with gastrointestinal cancer. The delegates will gain a greater understanding of current clinical practices in gastrointestinal malignancies with lectures by high profile international speakers, with presentations of cutting-edge research and clinical practice, clinical case discussions, seminars and with a wide range of submitted papers. IGICC will create opportunities for participants to present and share experiences, explore new directions and debate topics with international experts.

I cordially invite you to participate in this meeting by attending and submitting your scientific work as an abstract to be considered for presentation in IGICC 2022.

We are looking forward to meeting you for Istanbul IGICC 2022.

Prof Dr Şuayib Yalçın


JIPO and WIN Join Forces to Promote Immunotherapy and Precision Oncology in 2022

January 4, 2022 - The Journal of Immunotherapy and Precision Oncology (jipoonline.og) and WIN Consortium ( are proud to announce a strategic partnership for 2022.

Aung Naing, MD, Editor-in-Chief of JIPO says, "We at JIPO are excited about our collaboration with WIN. Our shared vision is to advance clinical practice of immunotherapy and precision oncology that transforms patient care. JIPO is a peer-reviewed, open access journal with a fair and efficient double-blinded review process. Our mission is to disseminate accurate scientific knowledge, including both positive and negative studies, related to translational science and clinical medicine.”  Naing further elaborates, "Our editorial board comprises renowned physicians and physician-scientists from diverse backgrounds and from different parts of the world. Our collaboration with WIN will enable us to realize our shared vision."

Razelle Kurzrock, MD, Chief Medical Officer of WIN says, “JIPO is positioned to have a high impact on the entire field of immunotherapy and precision oncology. The Worldwide Innovative Network (WIN) for precision medicine has goals well aligned with JIPO, considering its track record, including a multinational precision medicine that was the first to include transcriptomics as well as genomics in order to successfully match cancer patients with drugs.  We are proud to partner with JIPO to help bring the latest knowledge about innovative therapies to patients suffering from malignancies."

JIPO and WIN will cross-promote both organization’s activities throughout the year, including the WIN 2022 Symposium in Barcelona, Spain, October 29-30, 2022. Abstracts selected for presentation at the WIN meeting will be published in JIPO as a Conference Proceeding.

JIPO Editorial Fellow, Dr. Khalid Jazieh, will be interviewing members of WIN Leadership to highlight the collaboration and upcoming activities. Drs. Razelle Kurzrock, Vladimir Lazar, and Richard L. Schilsky will be interviewed. These interviews will be published on the JIPO YouTube channel in the coming weeks.

Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN, has been appointed to the JIPO Editorial Board to represent WIN Leadership. Dr. Lazar plans to contribute an editorial to the Journal in 2022. Dr. Kurzrock has published four articles in JIPO in 2019 and 2020 (complete list here). 

About JIPO

Journal of Immunotherapy and Precision Oncology (JIPO) is a peer-reviewed, open-access journal that is published quarterly by the Innovative Healthcare Institute (Cincinnati, OH, USA) ( JIPO aims to publish high-quality manuscripts related to the field of immunotherapy and precision oncology. For more information, please visit

Contact: Valerie Clark, JIPO Publishing Manager:

About WIN

WIN Consortium is a non-profit association headquartered in France. The WIN network assembles 35 world-class academic medical centers, industries (pharmaceutical and diagnostic companies), research organizations and patient advocates spanning 19 countries and 4 continents, aligned to launch trials using its genomics and transcriptomics biomarker platform to bolster Precision Oncology across the world. WIN is the organizer of the WIN symposia in Precision Oncology.

Contact: Vladimir Lazar, Chief Scientific and Operating Officer:

Download the full announcement



Interested in advertising? Please contact

Close Modal

or Create an Account

Close Modal
Close Modal